Jazz Pharmaceuticals PLC JAZZ
We take great care to ensure that the data presented and summarized in this overview for Jazz Pharmaceuticals plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JAZZ
View all-
Black Rock Inc. New York, NY7.07MShares$764 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.45MShares$697 Million0.02% of portfolio
-
State Street Corp Boston, MA2.46MShares$266 Million0.01% of portfolio
-
Lsv Asset Management Chicago, IL2.38MShares$257 Million0.59% of portfolio
-
Jpmorgan Chase & CO New York, NY1.49MShares$162 Million0.02% of portfolio
-
Polaris Capital Management, LLC Boston, MA1.43MShares$155 Million9.71% of portfolio
-
Capital World Investors Los Angeles, CA1.43MShares$154 Million0.03% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.37MShares$148 Million0.05% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.29MShares$140 Million0.4% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.17MShares$126 Million0.22% of portfolio
Latest Institutional Activity in JAZZ
Top Purchases
Top Sells
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Insider Transactions at JAZZ
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 07
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
163
-2.41%
|
$17,604
$108.83 P/Share
|
May 03
2024
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,000
-12.01%
|
$545,000
$109.65 P/Share
|
Apr 05
2024
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,736
-3.04%
|
$199,640
$115.21 P/Share
|
Mar 07
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,768
-21.14%
|
$205,088
$116.98 P/Share
|
Mar 06
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,936
-9.86%
|
$230,384
$119.18 P/Share
|
Mar 05
2024
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,622
-5.97%
|
$423,774
$117.53 P/Share
|
Mar 05
2024
|
Bruce C Cozadd Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
22,436
-4.96%
|
$2,625,012
$117.53 P/Share
|
Mar 05
2024
|
Robert Iannone EVP, Global Head of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
4,294
-6.46%
|
$502,398
$117.53 P/Share
|
Mar 05
2024
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,432
-7.62%
|
$401,544
$117.53 P/Share
|
Mar 05
2024
|
Samantha Pearce SVP, Head of Europe & Internat |
SELL
Payment of exercise price or tax liability
|
Direct |
2,474
-12.76%
|
$289,458
$117.53 P/Share
|
Mar 01
2024
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,987
+22.48%
|
-
|
Mar 01
2024
|
Mary Elizabeth Henderson SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,178
+24.52%
|
-
|
Mar 01
2024
|
Neena M Patil EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,348
+21.51%
|
-
|
Mar 01
2024
|
Samantha Pearce SVP, Head of Europe & Internat |
BUY
Grant, award, or other acquisition
|
Direct |
5,065
+20.71%
|
-
|
Mar 01
2024
|
Robert Iannone EVP, Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
16,928
+20.29%
|
-
|
Mar 01
2024
|
Renee D Gala President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
19,916
+24.7%
|
-
|
Mar 01
2024
|
Patrick Kennedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,423
+50.0%
|
-
|
Mar 01
2024
|
Bruce C Cozadd Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,187
+9.99%
|
-
|
Mar 01
2024
|
Philip L Johnson EVP & Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+30.05%
|
$1,428,000
$119.65 P/Share
|
Mar 01
2024
|
Philip L Johnson EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,932
+50.0%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 224K shares |
---|---|
Open market or private purchase | 12K shares |
Open market or private sale | 24.8K shares |
---|---|
Payment of exercise price or tax liability | 57.9K shares |
Sale (or disposition) back to the issuer | 1.39K shares |